Table 15.
Nanocarrier-based personalized cancer therapy
| Molecular Biomarker | Treatment Strategy | Clinical Outcome | Cost-effectiveness | References |
|---|---|---|---|---|
| EGFR mutation | Erlotinib-loaded nanocarriers targeted to EGFR | Partial response with improved quality of life | High | [297] |
| BRCA1 mutation | Poly(ADP-ribose) polymerase (PARP) inhibitor-loaded nanocarriers targeted to BRCA1 | Complete response with no adverse events | Moderate | [190] |
| KRAS mutation | Gemcitabine-loaded nanocarriers targeted to tumor stroma | Stable disease with improved pain control | Low |
[234] [298] |
| BRAF mutation | Vemurafenib-loaded nanocarriers targeted to BRAF | Complete response with skin rash | High | [299] |
| KRAS wild-type | Irinotecan-loaded nanocarriers targeted to CD44v6 | Stable disease with improved quality of life | Moderate | [218] |
| BRCA2 mutation | Doxorubicin-loaded nanocarriers targeted to BRCA2 | Partial response with improved pain control | High | [300] |
| HER2 overexpression | Trastuzumab-loaded nanocarriers targeted to HER2 | Complete response with no adverse events | High | [301] |
| KRAS mutation | Paclitaxel-loaded nanocarriers targeted to tumor stroma | Stable disease with improved appetite | Low | [302] |
| AR overexpression | Enzalutamide-loaded nanocarriers targeted to AR | Complete response with no adverse events | High | [303] |
| KRAS mutation | Gemcitabine-loaded nanocarriers targeted to tumor stroma | Partial response with improved appetite | Low |
[234] [220] |
| HER2 overexpression | Trastuzumab-loaded nanocarriers targeted to HER2 | Complete response with no adverse events | High |
[221] [301] |
| BRAF mutation | Cetuximab-loaded nanocarriers targeted to EGFR | Partial response with improved quality of life | Moderate | [304] |
| BRCA1 mutation | Olaparib-loaded nanocarriers targeted to BRCA1 | Partial response with improved pain control | High | [193] |
| ALK rearrangement | Crizotinib-loaded nanocarriers targeted to ALK | Complete response with improved appetite | High | [305] |
| KRAS mutation | 5-Fluorouracil-loaded nanocarriers targeted to tumor stroma | Stable disease with improved quality of life | Low | [95] |
| HER2 overexpression | Lapatinib-loaded nanocarriers targeted to HER2 | Partial response with improved appetite | Moderate | [306] |
| BRAF mutation | Dabrafenib-loaded nanocarriers targeted to BRAF | Complete response with skin rash | High | [267] |
| AR overexpression | Abiraterone-loaded nanocarriers targeted to AR | Partial response with improved quality of life | High |
[307] [219] |
| PARP1 overexpression | Olaparib-loaded nanocarriers targeted to PARP1 | Partial response with no adverse events | High | [308] |